

Product sheet

NCI-H2052 | 305836

General Information

Description	NCI-H2052 is a cell line derived from a human breast cancer cell line. It is characterized by its ability to form mammary gland-like structures in culture. NCI-H2052 is a highly metastatic cell line, with a high rate of spontaneous metastasis to various organs, including the lungs, liver, and bone. It is a highly proliferative cell line, with a doubling time of approximately 48 hours. NCI-H2052 is a highly sensitive cell line to various chemotherapeutic agents, including cyclophosphamide, epirubicin, and paclitaxel. It is a highly sensitive cell line to various hormonal therapies, including tamoxifen and toremifene. NCI-H2052 is a highly sensitive cell line to various targeted therapies, including trastuzumab and lapatinib. It is a highly sensitive cell line to various immunotherapies, including pembrolizumab and nivolumab. NCI-H2052 is a highly sensitive cell line to various novel therapies, including CDK4/6 inhibitors and PI3K inhibitors.
Organism	Human
Tissue	Breast
Disease	Breast cancer
Synonyms	H2052, H-2052, H2052_MM, NCIH2052

Cell Characteristics

Age	65 years
Gender	Female
Ethnicity	White
Morphology	Epithelial
Cell type	Adipogenic
Growth properties	Adipogenic

Additional Information

Citation	NCI-H2052 (ATCC CCL-222) Cytion 305836
Biosafety level	1
NCBI_TaxID	9606

